Related Experiment Video
Updated: Jul 30, 2026
08:12
Intramyocardial Cell Delivery: Observations in Murine Hearts
Published on: January 24, 2014
Intravenous magnesium therapy in acute myocardial infarction
E M Hampton1, D D Whang, R Whang
1Pharmacokinetic Dosing and Research Unit, Department of Veterans Affairs Medical Center, Oklahoma City, OK 73104.
The Annals of Pharmacotherapy
|February 1, 1994
Summary
Intravenous magnesium (Mg2+) shows promise in reducing mortality and arrhythmias after acute myocardial infarction (AMI). Further large-scale trials are needed to confirm these benefits and determine optimal dosage.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Acute myocardial infarction (AMI) is a leading cause of mortality.
- Magnesium (Mg2+) plays a crucial role in cardiac function.
- Serum Mg2+ levels may be altered in AMI patients.
Purpose of the Study:
- To review clinical trials on intravenous Mg2+ for AMI.
- To summarize findings on Mg2+ efficacy in AMI.
- To discuss potential mechanisms of Mg2+ action in AMI.
Main Methods:
- MEDLINE search for pertinent literature.
- Selection of randomized and/or placebo-controlled trials.
- Review of eight trials with adequate design and patient numbers.
Main Results:
- Intravenous Mg2+ may reduce immediate and long-term morbidity and mortality post-MI.
- Six of eight trials showed decreased arrhythmia incidence.
- Five of six trials indicated reduced mortality rates, particularly within 30 days and up to one year post-MI.
Conclusions:
- Intravenous Mg2+ shows promise for AMI therapy.
- Additional large-scale, multicenter trials are necessary.
- Avoid Mg2+ in patients with significant sinoatrial or AV conduction disturbances.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:22Myocarditis IV: Nursing Management
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
01:30Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...